Covariate | Adjusted HR | 95% CI | P-value |
---|---|---|---|
Rituximab exposure | 0.71 | 0.38, 1.34 | 0.29 |
Male gender | 0.68 | 0.35, 1.32 | 1.32 |
Caucasian | 0.90 | 0.50, 1.61 | 0.72 |
Region (reference: Midwest) | |||
Northeast | 0.74 | 0.28, 1.91 | 0.53 |
South | 0.70 | 0.33, 1.47 | 0.35 |
West | 1.09 | 0.40, 2.95 | 0.87 |
Length of Initial Stay (days) | 0.98 | 0.94, 1.03 | 0.41 |
ICU status | 1.41 | 0.61, 3.25 | 0.43 |
Receipt of PT | 4.81 | 1.14, 20.29 | 0.03 |
Receipt of PLEX | 1.01 | 0.49, 2.08 | 0.98 |
Glucocorticoid (reference: oral only) | |||
Intravenous only | 0.88 | 0.28, 2.72 | 0.82 |
Oral + intravenous | 1.72 | 0.57, 5.18 | 0.33 |